retatrutide type 2 diabetes trial improves blood sugar and weight loss in The numbers from Lilly's Phase

Our findings highlight the beneficial effects of GLP-1 RAs in improving survival and reducing adverse cardiac and kidney events in individuals with type 2 diabetes and AKD

The need for lifestyle changes in addition to medicine is also emphasized in the study as a key component of effective weight management

Nutrition and Training Recommendations Peptides are tools, not magic

GlucoBooster addresses that swing with a two-punch combo: 300 mg berberine to slow glucose release and 500 mg Gymnema sylvestre to mute sweet-taste receptors so dessert loses its appeal

IBS-D: Diarrhea-Predominant Relief For individuals living with IBS-D, the primary challenge is rapid transit through the colon, leading to frequent, loose stools and a sense of urgency

Over 18 months, about nine out of every 10,000 people in the GLP-1 group were diagnosed with ischemic optic neuropathy, compared with about six out of 10,000 in the GLT2 inhibitor group and about four out of 10,000 in the DPP4 inhibitor group